scholarly journals Preventiometer, a Novel Wellness Assessment Device, Used With Healthy Volunteers: A Phase 2 Study

2021 ◽  
Vol 10 ◽  
pp. 216495612110450
Author(s):  
Sanjeev Nanda ◽  
Tony Y. Chon ◽  
Saswati Mahapatra ◽  
Stephanie A. Lindeen ◽  
Karen M. Fischer ◽  
...  

Background We previously reported on a pilot study to assess the incorporation of a novel wellness assessment device, the Preventiometer (iPEx5 GmbH, Greifswald, Germany), into an academic medical practice. The present follow-up study expands on those data and evaluates the acceptability of the assessment process in a larger sample population. Objective The aim of this study was to evaluate participant satisfaction with the Preventiometer wellness assessment. Methods A total of 60 healthy volunteers participated. Each participant underwent a comprehensive wellness assessment with the Preventiometer and received data from more than 30 diagnostic tests. A 32-question survey (with a numeric rating scale from 0 to 10) was used to rate the wellness assessment tests and participants’ impressions of the wellness assessment. Results Each assessment had a significantly higher rating than 7 ( P < .001), and the majority of participants agreed or strongly agreed that they were satisfied (98.3%), and they strongly agreed that they were engaged the entire time (93.2%), and liked the instant test results feature of the Preventiometer device (93.2%). Conclusion This study confirms findings from our previous pilot study regarding the feasibility of the Preventiometer as a wellness assessment tool. The study further demonstrated that 98% of participants were satisfied with the assessment and that all of them would recommend it to others.

2021 ◽  
Vol 104 (3) ◽  
pp. 460-465

Background: The prevalence of spasticity in multiple sclerosis (MS) patients is nearly 90%. Most patients do not respond to current anti-spastic medications. Objective: To evaluate the efficacy and safety of Government Pharmaceutical Organization cannabis extract (GPOCE) in the treatment of spasticity in MS patients in Thailand. Materials and Methods: This prospective pilot study in patients diagnosed with MS whose spasticity was not relieved under current spasticity treatments, was performed between November 2019 and June 2020. The GPOCE formulation of THC:CBD 1:1 was administered to all patients. The treatment outcomes were determined at 12 weeks and compared with their baseline. Results: Seven patients participated in the present study. Among these, two patients withdrew after receiving only a small dose of GPOCE. Finally, five patients were included in the final analysis. The primary outcome was a reduction in the Modified Ashworth Score (MAS), which decreased among participants from a baseline of 15 (IQR 12 to 19) to 6 (IQR 1 to 12) (p=0.043). The key secondary outcome was a clinically relevant response (CRR), which was defined as a reduction of the spasticity Numeric Rating Scale (NRS) of more than thirty percent compared to baseline. Four patients (80%) achieved CRR. Moreover, the overall spasticity NRS decreased from a median of 6 (IQR5 to 7) to 2 (IQR2 to 3). A reduction of other NRS parameters, including fatigue, pain, tremor, sleep, spasm, anxiety, and depression, was also observed after treatment. Moreover, GPOCE was generally well tolerated. Conclusion: GPOCE is useful in treating spasticity in patients with MS. The safety profile is acceptable under the supervision of a health care provider. Keywords: Multiple sclerosis (MS), Cannabis extract, Spasticity


Author(s):  
Tony Luczak ◽  
Reuben F. Burch V ◽  
Brian Smith ◽  
John Lamberth ◽  
Daniel Carruth ◽  
...  

Background: Assessing basketball shoe comfort and fit as personal protection equipment (PPE) at the collegiate level is unique. Objective: The purpose of Part II in this pilot study was to examine the effect of shoe design on the perception of comfort and fit after performing an acute series of jumps in elite male and female National Collegiate Athletic Association (NCAA) Division 1 basketball student-athletes. Method: A total of sixteen basketball student-athletes (six males, ten females) performed two rounds of acute series of four styled basketball jumps on two ForceDecksTM Force Platforms while trying to maximize jump height by tapping VertecTM Jump Vanes. The male student-athletes selected the AdidasTM Harden Vol. 3 and the AdidasTM SM Pro basketball shoes. The female student-athletes selected the Adidas Harden Vol. 3 and the Adidas Captain Marvel basketball shoes. Upon completion of each round of jumps, the student-athlete recorded their perception of comfort on a 110mm Visual Analog Scale (VAS) and fit on a seven-point Likert rating scale based against their most comfortable basketball shoes ever worn. Results: Results of this pilot study reported, on average, the male student-athletes preferred comfort and fit of the Adidas SM Pro basketball shoes and the female student-athletes preferred the Adidas Harden Vol. 3 basketball shoe, though differences were non-significant at p > 0.05. Conclusion: The use of a human factors assessment tool to evaluate basketball shoe comfort and fit and the influence of rated comfort and fit parameters on basketball jumping performance proved viable.


2017 ◽  
Vol 45 (4) ◽  
pp. 459-465 ◽  
Author(s):  
P. J. Peyton ◽  
C. Wu ◽  
T. Jacobson ◽  
M. Hogg ◽  
F. Zia ◽  
...  

Chronic postsurgical pain (CPSP) is a common and debilitating complication of major surgery. We undertook a pilot study at three hospitals to assess the feasibility of a proposed large multicentre placebo-controlled randomised trial of intravenous perioperative ketamine to reduce the incidence of CPSP. Ketamine, 0.5 mg/kg pre-incision, 0.25 mg/kg/hour intraoperatively and 0.1 mg/kg/hour for 24 hours, or placebo, was administered to 80 patients, recruited over a 15-month period, undergoing abdominal or thoracic surgery under general anaesthesia. The primary endpoint was CPSP in the area of the surgery reported at six-month telephone follow-up using a structured questionnaire. Fourteen patients (17.5%) reported CPSP (relative risk [95% confidence interval] if received ketamine 1.18 [0.70 to 1.98], P=0.56). Four patients in the treatment group and three in the control group reported ongoing analgesic use to treat CPSP and two patients in each group reported their worst pain in the previous 24 hours at ≥3/10 at six months. There were no significant differences in adverse event rates, quality of recovery scores, or cumulative morphine equivalents consumption in the first 72 hours. Numeric Rating Scale pain scores (median [interquartile range]) for average pain in the previous 24 hours among those patients reporting CPSP were 17.5 [0 to 40] /100 with no difference between treatment groups. A large (n=4,000 to 5,000) adequately powered multicentre trial is feasible using this population and methodology.


2015 ◽  
Vol 28 (1) ◽  
pp. 32 ◽  
Author(s):  
Bon Sung Koo ◽  
Myung Jin Jung ◽  
Joon Ho Lee ◽  
Hee Cheol Jin ◽  
Jeong Seok Lee ◽  
...  

2008 ◽  
Vol 13 (3) ◽  
pp. 112-117 ◽  
Author(s):  
Chou I. Eyberg ◽  
Janine Pyrek

Abstract Products and technologies that aid health care professionals in vascular access practice save staff time, and while promoting patient safety and prevention of infection can provide excellent opportunities for evaluations to support evidence-based practice. This was an industry sponsored, prospective, single site, controlled, randomized clinical evaluation pilot study of two catheter dressings, 3M™ Tegaderm™ Chlorhexidine Gluconate (CHG) IV Securement Dressing (CHG gel dressing) (3M Health Care, St. Paul, MN) and BIOPATCH® Antimicrobial Dressing with Chlorhexidine Gluconate (BIOPATCH® Protective Disk with CHG, Johnson & Johnson, Somerville, NJ). Twelve intravascular (IV) therapy health care professionals (Clinicians) were asked for their professional evaluations of the catheter dressings: the ease of application and performance factors featured in specific questions. Catheters were secured on 12 healthy volunteers to simulate inserted jugular catheters (IJ) and peripherally inserted central catheters (PICC) using StatLock® PICC Plus and 3M™ Steri-Strip™. Each clinician applied and removed one CHG gel dressing and one CHG disk on one simulated PICC and one simulated IJ site, according to the manufacturers' instructions. The clinicians concluded, based upon a 1 to 5 rating scale, that the CHG gel dressing is better in regard to ease of application, ease of applying correctly, ease of removal, ability to visualize the insertion site, ease of training another clinician to apply the dressing, and more intuitive application. Twelve out of 12 clinicians favored the CHG gel dressing over the CHG disk in overall performance.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 416-416
Author(s):  
Margaret Guy ◽  
Rehan Qayyum ◽  
Pamela Derby ◽  
Nicole Carter ◽  
Jessica Keiser ◽  
...  

Introduction: Sickle cell disease (SCD) vaso-occlusive crisis (VOC) often requires hospitalization, but SCD pain may be present prior to admission and persist past discharge, similar to many acute-on-chronic painful conditions. In practice, readiness for discharge during VOC is a judgment and/or negotiation between patients and their caregivers. Subjective pain intensity, rated on a unidimensional continuous or numeric rating scale, communicates neither readiness for discharge, nor patients' multidimensional pain experience. Inpatient multidimensional pain scales that incorporate concepts like physical function may require too much time and/or impose a high, daily respondent burden on uncomfortable SCD respondents. We found no well-established brief daily adult inpatient multidimensional assessment scale for SCD, but found a pediatric daily function SCD scale, as well as scales used in systemic lupus erythematous and fibromyalgia. We therefore developed and validated the functional status-based pain-assessment (FSPA) survey meant to improve evaluation of readiness for discharge during VOC. Methods: FSPA was created using concepts from the above scales, plus input from inpatient management experts familiar with SCD, including physicians, nurse practitioners, pharmacists, and bedside nurses. FSPA helps assess the full spectrum of a patient's functional limitations due to pain. FSPA consists of tasks that are recorded using the patient's self-reported ability (5 point Likert scale ranging from "very easy" to "very difficult") to complete activities including sleeping, watching TV, walking around the room, or eating a meal in a chair. FPSA was designed to be on a health literacy grade of one. Patients were asked to complete FSPA daily at approximately the same time of day. Concurrently, they were asked to rate their pain using a Numeric Rating Scale (NRS, 0-10). Surveys were administered on a preselected nursing unit from January 2018 to June of 2019. Means (standard deviations) or frequencies were used to summarize data. Pearson's correlation was used to examine the relationship between the two continuous variables. Believing readiness for discharge to be a single factor, we performed confirmatory factor analysis (CFA) using structural equation modeling for determining the empirical validity of having a one-factor solution for the FSPA tool. We used item response theory analysis to determine the characteristics of each item using graded response model within a 2-parameter framework. All analyses were performed using Stata 14.0. Results: During the study period, 504 assessments from 86 unique patients over 170 distinct admissions were completed. Of the 86 unique patients, 54% were females with mean age of 31.5 (SD8.0) years. The length of stay was 7.1 (SD6.9) days; minimum 0 days, max 38 days. NRS mean was 6.8 ±1.9 and FSPA mean was 27±8.0. Correlation was moderate and highly significant (Pearson's r = -.4342, p &lt;.0001). The CFA indicated that the one-factor structure was a good fit for the data using routine diagnostic statistics (Figure). Using item response theory analysis, we found that the item discrimination varied from 0.56 to 4.1 while difficulty of the items covered broadly the latent variable of the functional status with pain with values ranging from -2.8 to 7.5. Conclusions: Development and validation of FPSA, while not complete, has yielded a brief assessment tool which may be used daily to improve communication between adult SCD VOC patients and their inpatient clinicians. FPSA may aid the judgment and negotiation of readiness for discharge of these patients, in order to prevent unnecessarily short or long hospital lengths of stay as well as improve patient and provider satisfaction. Future validation could compare FSPA to other longer-term pain and functional assessment tools, determine its ability to predict VOC discharge, and determine whether its use changes VOC discharge behavior. Figure Disclosures Smith: Novartis: Consultancy, Honoraria.


2019 ◽  
Vol 28 (10) ◽  
pp. 647-655
Author(s):  
Mark MPM Jansen ◽  
Aukje ALM van de Ven ◽  
Pieter GM van der Valk ◽  
Oliver HG Wilder-Smith

Objective: Pain is a common and disabling symptom in patients with leg ulcers. Clinical quantification of pain mostly depends on subjective pain reports, which do not reveal underlying mechanisms. The aim of this pilot study is to identify mechanisms underlying the pain in patients with leg ulcers by documenting alterations in pain processing using quantitative sensory testing. Methods: In nine ulcer patients the mechanical sensory thresholds and the mechanical pain thresholds were determined by Semmes-Weinstein monofilaments (SWM) at three different sites: on the contralateral (unaffected) leg, on the skin of the affected leg 10cm from the ulcer margin, and on the affected leg, close (1–2cm) to the ulcer margin. Besides the mechanical sensory thresholds and mechanical pain thresholds, pain at the site of the ulcer, using an 11-point numeric rating scale (NRS), was documented. Results: Mechanical sensory thresholds were increased in all subjects. Almost half (44%) of patients consistently showed allodynia at the unaffected site. The lowering of mechanical pain thresholds correlated with higher scores on the NRS. Conclusion: All patients showed diminished touch and/or protective sensation, which might have contributed to ulcer development via (partial) loss of protective function. The allodynia at the unaffected site suggests the presence of central sensitisation of pain processing.


Pain ◽  
2010 ◽  
Vol 150 (2) ◽  
pp. 231-236 ◽  
Author(s):  
Jean C. Solodiuk ◽  
Jennifer Scott-Sutherland ◽  
Margie Meyers ◽  
Beth Myette ◽  
Christine Shusterman ◽  
...  

2020 ◽  
Vol 34 (9) ◽  
pp. 1274-1278
Author(s):  
Juho T Lehto ◽  
Sirpa Leivo-Korpela ◽  
Tarja Korhonen ◽  
Heidi A Rantala ◽  
Hanna Raunio ◽  
...  

Background: Noninvasive ventilation may relieve dyspnea in advanced diseases, but noninvasive ventilation through mouthpiece has not been tested in palliative care. Aim: To assess the feasibility of mouthpiece ventilation in relieving dyspnea among patients with advanced disease. Design: In this prospective single-arm pilot study, the change in dyspnea by mouthpiece ventilation was measured with numeric rating scale (0–10) and 100-mm visual analogue scale. Overall, benefit and adverse events of the therapy were also assessed. Setting/participants: Twenty-two patients with an advanced disease and dyspnea from the Tampere University Hospital or Pirkanmaa Hospice were treated with mouthpiece ventilation. The patients used mouthpiece ventilation as long as they preferred, but for a minimum of 5 min. Results: After the treatment period lasting a median of 13.5 min, mean decrease in dyspnea was −1.1 (95 % confidence interval = −2.2 to −0.1, p = 0.034) on numeric rating scale and −11.8 mm (95 % confidence interval = −19.9 to −3.7, p = 0.006) on visual analogue scale. Nonetheless, there was a high variability in this effect between individual patients. About half of the patients found mouthpiece ventilation beneficial. No serious adverse events occurred, but dry mouth was the most common adverse event. Anxiety did not increase with mouthpiece ventilation. Conclusion: Mouthpiece ventilation is feasible and may relieve dyspnea in some patients with an advanced disease. Further studies are needed, and these might concentrate on stable patients in early palliative care. Before initiation, this study was registered at clinicaltrials.gov (study no. NCT03012737).


Sign in / Sign up

Export Citation Format

Share Document